Sort   by:  
 Page size 
ProteomicsDetermination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in MLL1-rearranged AML cells
We treated MLL1-rearranged AML MOLM13 cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for different time intervals (up to 48 hours) to measure the time-dependent changes to the AML proteome
ORGANISM(S): Homo sapiens (Human) 
2025-05-26 | PXD047965 | Pride
Mll1-rearranged aml Chromatin remodelers Fhd-286 
UnknownThe menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Not available
S-EPMC8832476 | biostudies-literature
ProteomicsEffect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053548 | Pride
Secondary aml Sndx-50469 Tasquinimod Cdk7 inhibitor Fhd-286 
ProteomicsProject title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells
MOLM13 cells and patient-derived de novo AML cells with MLL1 rearrangement were treated with 100 nM of FHD-286 or 100 nM of AU15330, a dual BRG1/BRM protein degrader for 48 hours. The goal was to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitor...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD055994 | Pride
Fhd-286 Au15330 Protac Chromatin 
UnknownMLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
Not available
S-EPMC5598468 | biostudies-literature
UnknownA novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Not available
S-EPMC9960487 | biostudies-literature
UnknownThe Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Not available
S-EPMC5701546 | biostudies-literature
GenomicsNon-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML [ChIP-Seq]
Non-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML [ChIP-Seq]
PRJNA1047912 | ENA
GenomicsNon-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML [RNA-seq]
Non-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML [RNA-seq]
PRJNA1146477 | ENA
GenomicsNon-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML
Non-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML
PRJNA1047909 | ENA
Sort   by:  
 Page size